Valuation: Verastem, Inc.

Market Cap 618M 529M 495M 453M 850M 59.1B 862M 5.85B 2.28B 29.69B 2.32B 2.27B 98.19B P/E 2026 *
-4.25x
P/E 2027 * -5.85x
Enterprise Value 660M 565M 529M 484M 908M 63.1B 920M 6.25B 2.44B 31.7B 2.48B 2.42B 105B EV / Sales 2026 *
5.66x
EV / Sales 2027 * 3.41x
Free-Float
99.1%
Yield 2026 *
-
Yield 2027 * -
1 day+1.03%
1 week+5.24%
Current month+19.40%
1 month+15.42%
3 months+62.18%
6 months+21.49%
Current year-10.30%
1 week 6.45
Extreme 6.45
7.86
1 month 5.54
Extreme 5.54
7.86
Current year 3.43
Extreme 3.43
8.88
1 year 3.43
Extreme 3.43
11.24
3 years 2.1
Extreme 2.1
14.22
5 years 2.1
Extreme 2.1
42.96
10 years 2.1
Extreme 2.1
124.2
Manager TitleAgeSince
Chief Executive Officer 65 01/08/2023
Director of Finance/CFO 39 31/10/2022
Chief Tech/Sci/R&D Officer - 18/04/2024
Director TitleAgeSince
Chairman 62 -
Director/Board Member 65 01/08/2023
Director/Board Member 69 03/05/2017
Date Insider Type Main position Quantity % Market Cap.
3/8/26 Sell

Chief Executive Officer

-1,302 0.0021%
21/5/26 Free

Chairman

36,000 0.0410%
21/5/26 Free

Director

36,000 0.0410%
Change 5-day change 1-year change 3-year change Capi.($)
+1.03%+5.24%-19.76%-34.79% 618M
-3.00%+0.33%+77.39%+109.41% 73.96B
+1.90%+23.53%+56.60%+97.76% 64.66B
+1.07%+2.24%-4.59%+475.07% 27.32B
+4.39%+24.23%+4.41%-1.60% 27.86B
+2.74%+11.55%+66.56%+27.34% 25.97B
+0.47%+6.12%+36.66%-13.79% 19.98B
+1.82%-3.11%+245.72%+423.83% 17.84B
+0.94%+2.38%+24.83%+552.12% 16.24B
+1.23%+6.05%+40.38%+154.28% 13.3B
Average +1.26%+5.77%+52.82%+178.96% 28.77B
Weighted average by Cap. +0.69%+6.65%+59.61%+161.05%

Financials

2026 *2027 *
Net sales 116M 99.75M 93.33M 85.43M 160M 11.14B 162M 1.1B 430M 5.6B 437M 428M 18.51B 181M 155M 145M 133M 249M 17.33B 253M 1.72B 669M 8.71B 680M 665M 28.79B
Net income -166M -142M -133M -122M -228M -15.87B -231M -1.57B -613M -7.97B -623M -609M -26.37B -157M -135M -126M -115M -216M -15.03B -219M -1.49B -580M -7.55B -590M -577M -24.97B
Net Debt 41.9M 35.89M 33.58M 30.74M 57.69M 4.01B 58.45M 397M 155M 2.01B 157M 154M 6.66B -
Logo Verastem, Inc.
Verastem, Inc. is a late-stage development biopharmaceutical company, which focuses on the development and commercialization of new medicines to improve the lives of patients diagnosed with ras sarcoma (RAS)/ mitogen-activated pathway kinase (MAPK) pathway-driven cancers. Its product candidates include avutometinib and defactinib. Avutometinib is an oral RAF/MEK clamp that inhibits MEK1/2 kinase activities and induces inactive complexes of MEK with A-Raf proto-oncogene, potentially serine/threonine kinase (ARAF), B-Raf proto-oncogene serine/threonine kinase (BRAF) and C-raf proto-oncogene serine/threonine kinase, creating antitumor response through maximal RAS/MAPK pathway inhibition. Defactinib is an oral, selective inhibitor of FAK and proline-rich tyrosine kinase (PYK2), the two members of the focal adhesion kinase family of non-receptor protein tyrosine kinases. FAK and PYK2 integrate signals from integrin and growth factor receptors to regulate cell proliferation.
Employees
102
Date Price Change Volume
22/08/26 USD 6.923 +1.51% 440,153
20/08/26 USD 6.820 -6.51% 2,294,170
19/08/26 USD 7.295 -1.82% 2,371,623
18/08/26 USD 7.430 +3.48% 2,924,317
17/08/26 USD 7.180 +9.12% 2,284,012
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
6.820USD
Average target price
14.75USD
Spread / Average Target
+116.28%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VSTM Stock